Artios is advancing alnodesertib, an oral ATR inhibitor with an N-linked sulfoximine intended to improve selectivity within the PIKK family. Early combination results with irinotecan reported significant improvements in objective response rate in ATM-negative patients. The initial readout supported an FDA Fast Track designation in metastatic colorectal cancer, positioning alnodesertib for accelerated clinical development in genetically defined subgroups where ATR pathway inhibition may help overcome DNA repair resistance. Industry impact: ATR-targeting strategies continue to attract attention for ATM-deficient tumors, and Fast Track status can bring faster trial starts and clearer regulatory engagement for combination regimens.